Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Hatzakis, 2015, The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm: volume 2, J Viral Hepat, 22, 26, 10.1111/jvh.12351 Smith, 2014, Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource, Hepatology, 59, 318, 10.1002/hep.26744 Messina, 2015, Global distribution and prevalence of hepatitis C virus genotypes, Hepatology, 61, 77, 10.1002/hep.27259 Asselah, 2016, Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives, Liver Int, 36, 47, 10.1111/liv.13027 2016 2016 HARVONI (ledipasvir and sofosbuvir) tablets. Prescribing information. Foster City, CA: Gilead Sciences, 2015. 2016 2017 2017, EASL. Recommendations on treatment of hepatitis C 2016, J Hepatol, 66, 153, 10.1016/j.jhep.2016.09.001 Ng, 2017, In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir, Antimicrob Agents Chemother, 61, 10.1128/AAC.02558-16 Kwo, 2017, Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis, J Hepatol, 67, 263, 10.1016/j.jhep.2017.03.039 Westfall, 2001, Optimally weighted, fixed sequence and gatekeeper multiple testing procedures, J Stat Plan Inference, 99, 25, 10.1016/S0378-3758(01)00077-5 Schinazi, 2017, From HCV to HBV cure, Liver Int, 37, 73, 10.1111/liv.13324 Kwo, 2011, The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors, Gut Liver, 5, 406, 10.5009/gnl.2011.5.4.406 Chae, 2013, Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives, Scientific World Journal, 2013, 704912, 10.1155/2013/704912 Banerjee, 2016, Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy, Aliment Pharmacol Ther, 43, 674, 10.1111/apt.13514 2015, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, Hepatology, 62, 932, 10.1002/hep.27950 Foster, 2015, Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection, N Engl J Med, 373, 2608, 10.1056/NEJMoa1512612 Feld, 2015, Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection, N Engl J Med, 373, 2599, 10.1056/NEJMoa1512610 Jacobson, 2017, Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials, Gastroenterology, 153, 113, 10.1053/j.gastro.2017.03.047 2017 2017 Cheng, 2016, In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir, Antimicrob Agents Chemother, 60, 1847, 10.1128/AAC.02524-15 Wang, 2014, Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity, Antimicrob Agents Chemother, 58, 5155, 10.1128/AAC.02788-14 Kwo, 2017, High SVR rates upon 8- or 12-week treatment with glecaprevir and pibrentasvir in patients with chronic HCV genotype 1-6 infection without cirrhosis, J Hepatol, 67, 263, 10.1016/j.jhep.2017.03.039 Zeuzem S, Feld J, Wang S, et al. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection. The Liver Meeting, Boston, MA, 2016. Ng, 2016, Analysis of HCV variants in the MAGELLAN-I study (part 1): ABT-493 and ABT-530 combination therapy of genotype 1-infected patients who had failed prior direct acting antiviral-containing regimens, Hepatology, 64, 417A Muir, 2016, High SVR rates with ABT-493 + ABT-530 co-administered for 8 weeks in non-cirrhotic patients with HCV genotype 3 infection, Hepatology, 64, 183 Forns, 2017, Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial, Lancet Infectious Diseases, 17, 1062, 10.1016/S1473-3099(17)30496-6 Puoti M, Foster G, Wang S, et al. High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy analysis of genotype 1–6 patients without cirrhosis. International Liver Congress, Amsterdam, Netherlands, 2017.